Unlike the other death-inducing ligands, TRAIL, a member of the TNF superfamily of cytokines, has been appealing in the development of biotherapeutic drug candidates that activate TRAIL-receptors (TRAIL-Rs) to induce apoptosis in cancer cells, with little or no effect in normal tissues [50–53]. The gene discussed is TNFSF10; the disease is cancer.